Niosomal co-delivery of metformin and telaglenastat: A targeted nanotherapeutic strategy for breast cancer treatment and metastasis suppression in 2D and 3D models.

Overexpression of glucose transporter-1 (GLUT-1) and glutaminase-1 (GLS-1) underlies the metabolic dependence of breast cancer cells on glucose and glutamine. Exploiting this vulnerability, a dual-drug niosomal delivery system was developed for the e…

Preview only. Read the full abstract at the source